Department of Organ Transplantation.
Department of Pathology.
Transplant Proc. 2021 Oct;53(8):2503-2508. doi: 10.1016/j.transproceed.2021.08.006. Epub 2021 Sep 2.
Patients with early-stage renal cell carcinoma (RCC) are considered to be eligible donors. Although preliminary experience in using kidneys of specific pathologic types, mainly those with small renal masses (SRMs), have been established, multiorgan utilization of the same donor with SRMs is limited.
One deceased donor whose left-side kidney was diagnosed with Fuhrman grade I RCC was included. The tumor mass in the kidney was removed through partial nephrectomy according to the gold standard. Then, 3 transplant surgeries were performed, in which 1 recipient accepted kidney transplant after tumor exeresis, 1 simultaneous heart-kidney (the contralateral one) transplant, and 1 liver transplant. Recipients were followed up according to our standard protocol for renal cancers. (All allografts were allocated in compliance with the Declaration of Helsinki and the Declaration of Istanbul.) RESULTS: After 32 months, no radiographic findings showed any morphologic changes of the lesion, and all patients were in good condition, with neither tumor recurrence nor allograft rejection or infection. No complaints such as pain, oliguria, dyspnea, nausea, or fatigue were recorded.
To the best of knowledge, this initial work takes the lead in elaborating the organ utilization of multiorgan donors with SRMs. We hope the experience will provide support for cross discussion concerned with multiorgan transplant from tumor-affected donors in clinical practices, further expand the donor pool and address the donor shortage problem.
早期肾细胞癌(RCC)患者被认为符合捐献者标准。尽管已经有了使用特定病理类型肾脏的初步经验,主要是那些具有小肾肿瘤(SRM)的肾脏,但具有 SRM 的同一供体的多器官利用受到限制。
纳入了一名左肾诊断为 Fuhrman I 级 RCC 的已故捐献者。按照金标准,通过部分肾切除术切除肾脏中的肿瘤块。然后进行了 3 次移植手术,其中 1 名接受肿瘤切除后肾移植的受者、1 名同时心脏-肾(对侧)移植的受者和 1 名肝移植的受者。受者根据我们的肾癌标准随访方案进行随访。(所有同种异体移植物的分配均符合赫尔辛基宣言和伊斯坦布尔宣言。)
32 个月后,没有影像学发现病变有任何形态学变化,所有患者状况良好,既没有肿瘤复发,也没有移植物排斥或感染。没有记录到疼痛、少尿、呼吸困难、恶心或疲劳等投诉。
据我们所知,这项初步工作率先阐述了具有 SRM 的多器官捐献者的器官利用情况。我们希望这些经验将为临床实践中涉及肿瘤供体的多器官移植的交叉讨论提供支持,进一步扩大供体库并解决供体短缺问题。